<--GAT-->

Aspirin Appears to Be Safe for Some Heart Failure Patients

by U.S. Medicine

November 26, 2017

SAN FRANCISCO – Does use of aspirin increase heart failure (HF) hospitalization or risk of death in patients with reduced ejection fraction receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)?

That was the question addressed in a recent article in the journal JACC Heart Failure. The report pointed out that aspirin has been postulated to increase HF events in patients treated with ACE inhibitors or ARBs because of its cyclooxygenase inhibiting properties.1

The study team led by researchers from the San Francisco VAMC and the University of California San Francisco School of Medicine pointed out, however, that no large randomized trial has addressed the clinical relevance of this issue.

To help remedy the information deficit, researchers compared aspirin and warfarin for HF events — hospitalization, death, or both — in the 2,305 patients enrolled in the Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction (WARCEF)) trial. Nearly all of the patients were on ACE inhibitor or ARB treatment.

Overall, 432 HF hospitalization events occurred with aspirin — 10.7 per 100 patient-years — compared to 500 HF hospitalization events with warfarin — 12.4 per 100 patient-years. Study authors calculated the risk ratio at 0.87.

Even though, at a mean follow-up of 3.5 years, a much lower percentage of the aspirin group reached the combined outcome of hospitalization or death attributed to HF than the warfarin group — 19% vs. 23% — after adjustment for patient characteristics, researchers determined that the groups did not differ in risk for the combined outcome or for HF hospitalization alone, for an adjusted hazard ratio of 0.87 or first hospitalization alone (adjusted hazard ratio: 0.88).

“Among patients with HF with reduced ejection fraction in the WARCEF trial, there was no significant difference in risk of HF events between the aspirin and warfarin-treated patients. (Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction trial [WARCEF],” the researchers concluded. 

1.    Teerlink JR, Qian M, Bello NA, Freudenberger RS, Levin B, Di Tullio MR, GrahamS, Mann DL, Sacco RL, Mohr JP, Lip GYH, Labovitz AJ, Lee SC, Ponikowski P, LokDJ, Anker SD, Thompson JLP, Homma S; WARCEF Investigators. Aspirin Does NotIncrease Heart Failure Events in Heart Failure Patients: From the WARCEF Trial.JACC Heart Fail. 2017 Aug;5(8):603-610. doi: 10.1016/j.jchf.2017.04.011. PubMedPMID: 28774396; PubMed Central PMCID: PMC5570544.


Related Articles

VA Research Determines Which Beta Blocker Is Better in Heart Failure

ST. LOUIS—Current clinical guidelines recommend the use of beta blockers in all heart failure patients with with reduced ejection fraction (HFrEF). Which beta blocker to use—carvedilol or metoprolol succinate—remained unclear, however, according to a recent... View Article

New VA Analysis Refutes Link Between Heart Failure, Incident Cancer

With about 350,000 patients with heart failure diagnoses being treated in the VHA, recent studies suggesting that the cardiovascular condition increases risk of cancer have been worrisome.


U.S. Medicine Recommends


More From pharmacy clinical topics

Pharmacy

VA Hospitals First to Publicly Report Opioid Prescribing Rates

In January, the VA became the first hospital system in the United States to publicly post opioid prescribing rates.

Pharmacy

Long-term Opioid Prescribing Declines in VHA, Bucking National Trend

Extended Prescribing Dropped from 9.5% in 2012 to 6.2% in 2016 By Brenda L. Mooney IOWA CITY, IA—Long-term prescribing of opioid painkillers is on the decline at the VA, in contrast to what appears to be happening outside of federal medicine.

Pharmacy

VA Study Addresses Concerns About Anti-Epileptic Drugs, Suicidal Behavior Link

In 2008, the U.S. Food and Drug Administration issued an alert about increased risk for suicidal ideation and behavior for patients taking anti-epileptic drugs (AEDs).

Pharmacy

Using EMR to Improve Statin Adherence in MHS

STATESBORO, GA—What factors can cause delays in initiation of initial disease-modifying antirheumatic drug, or DMARD, in patients newly diagnosed with rheumatoid arthritis (RA)? A retrospective cohort descriptive study used administrative data from the TRICARE program... View Article

Pharmacy

Surveys Show Why VA Good Prescribing Practice Also Should Include Deprescribing

STATESBORO, GA—What factors can cause delays in initiation of initial disease-modifying antirheumatic drug, or DMARD, in patients newly diagnosed with rheumatoid arthritis (RA)? A retrospective cohort descriptive study used administrative data from the TRICARE program... View Article

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up